Exosomes are nano-sized extracellular vesicles responsible for cell-to-cell communication. They act as biological messengers, delivering growth factors, microRNAs, proteins, and signaling molecules that activate regeneration, modulate inflammation, and restore tissue homeostasis.
In aesthetic medicine, exosomes represent a shift from surface-level correction to true biological regeneration. Rather than indirectly stimulating tissues, they work at the cellular signaling level — where tissue repair and renewal actually begin.
Clinical outcomes, however, depend directly on the quality, purity, origin, and standardization of exosomes. This is precisely where ExoCoBio sets itself apart.
Why ExoCoBio exosomes are fundamentally different
ExoCoBio is a global biotechnology leader specializing exclusively in exosome-based regenerative solutions.
Why ExoCoBio is unique for clinical practice
The company applies a comprehensive scientific approach to exosome technology, ensuring consistency, safety, and clinical relevance.
At the core of ExoCoBio’s innovation is the patented ExoSCRT™ isolation technology, which enables the production of ultra-high purity exosomes with minimal contamination from proteins and cellular debris — a critical factor for clinical use.
Unlike “exosome-inspired” cosmetic products, ExoCoBio solutions contain a quantified and strictly controlled number of exosome particles per vial, verified under GMP-level standards. This allows clinicians to work with predictable compositions and reproducible outcomes.
Supported by more than 75 patents, continuous R&D, and millions of clinical applications worldwide, ExoCoBio does not sell a trend — it delivers a standardized regenerative technology designed for professional medical protocols.
Overview of ExoCoBio professional solutions:
ASCEplus Derma Signal Kit (SRLV)
Skin regeneration & rejuvenation
ASCEplus SRLV is a professional dual-vial exosome-based regenerative system designed to restore skin quality, elasticity, and barrier function. The product is intended for clinical use and seamless integration into modern aesthetic protocols.
Key mechanism of action
Exosomes promote dermal fibroblast activation and regulate extracellular matrix (ECM) remodeling. By delivering microRNAs and signaling proteins, exosomes stimulate collagen and elastin synthesis while simultaneously modulating inflammatory cascades and matrix metalloproteinase (MMP) activity.
This mechanism makes exosome therapy particularly valuable in cases of skin aging, post-acne changes, and impaired skin barrier function — situations where structural restoration is required rather than superficial masking.
Scientific profile
SRLV is based on the patented ExoSCRT™ technology, which ensures high-purity exosome isolation. The exosomes are derived from mesenchymal stem cells (MSCs), with a strictly standardized concentration of 5 billion ExoSCRT™ exosomes per vial, ensuring consistency and reproducibility.
Clinical indications
Loss of skin firmness and density, fine lines, enlarged pores, post-acne changes and atrophic scars, sensitive or reactive skin, impaired skin barrier, and post-procedure recovery.
Clinical value
ASCEplus SRLV acts as a regeneration amplifier and can be used as a standalone treatment or in combination with laser, RF, and microneedling procedures to enhance regenerative outcomes.
ASCEplus Scalp Care (HRLV)
Exosome therapy for hair and scalp health
ASCEplus HRLV is a targeted exosome therapy developed specifically for scalp regeneration and physiological hair growth support. The product addresses the underlying biological mechanisms of hair loss rather than providing temporary stimulation.
Key mechanism of action
Exosomes are involved in the regulation of Wnt/β-catenin signaling, a key pathway responsible for hair follicle cycling and activation.
MSC-derived exosomes have been shown to:
-
stimulate dermal papilla cell proliferation,
-
improve the follicular microenvironment,
-
reduce scalp inflammation.
As a result, exosome therapy targets the pathogenetic mechanisms of alopecia, supporting long-term scalp and hair restoration.
Scientific profile
HRLV utilizes high-purity exosomes isolated using ExoSCRT™ technology, with a standardized concentration of 10 billion ExoSCRT™ exosomes per vial, ensuring predictable and reproducible clinical performance.
Clinical indications
Diffuse and androgenetic hair loss, thinning hair and reduced density, scalp inflammation and seborrhea, dryness, flaking, and slow hair growth.
Clinical value
HRLV acts on inflammatory pathways and the follicular microenvironment, addressing the root causes of hair loss rather than offering short-term cosmetic stimulation.
ASCEplus Intimate Care (IRLV)
Regeneration and comfort for intimate zones
ASCEplus IRLV is an advanced exosome-based system developed for external intimate rejuvenation and tissue recovery. The product is designed for delicate regeneration in areas where aggressive treatments are not appropriate.
Key mechanism of action
Exosomes exhibit pronounced anti-inflammatory and regulatory effects, participating in tissue remodeling and epithelial barrier restoration.
Through intercellular communication, exosomes:
-
reduce inflammatory mediators,
-
support tissue structure recovery,
-
improve elasticity and hydration.
This mechanism is particularly important for sensitive areas requiring gentle yet effective regeneration.
Scientific profile
IRLV is based on plant-derived exosomes isolated from rose stem cells using ExoSCRT™ technology. Each vial contains a standardized concentration of 5 billion plant-derived exosomes, ensuring stability and consistency.
Clinical indications
Dryness and discomfort, reduced elasticity and tissue thinning, post-childbirth changes, increased sensitivity, and microbiome imbalance.
Clinical value
IRLV provides gentle yet clinically meaningful regeneration, restoring tissue quality and comfort without aggressive intervention and integrating easily into existing aesthetic and gynecological protocols.
Why clinics choose ExoCoBio
Working with ExoCoBio means integrating evidence-based regenerative medicine into everyday clinical practice. Standardized exosome therapy, predictable outcomes, and safe compatibility with device-based treatments create a high level of trust among both clinicians and patients.
ExoCoBio establishes a benchmark for what exosome technology should be — measurable, reproducible, and clinically meaningful.
